tbuckley/cabot-search huggingface dataset:
Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease
Authors: Kelly A. Shaw, Madeline Bertha, Tatyana Hofmekler, Pankaj Chopra, Tommi Vatanen, Abhiram Srivatsa, Jarod Prince, Archana Kumar, Cary Sauer, Michael E. Zwick, Glen A. Satten, Aleksandar D. Kostic, Jennifer G. Mulle, Ramnik J. Xavier, Subra Kugathasan
Journal: Genome Medicine (2016)

Gut microbiome dysbiosis has been demonstrated in subjects with newly diagnosed and chronic inflammatory bowel disease (IBD). In this study we sought to explore longitudinal changes in dysbiosis and ascertain associations between dysbiosis and markers of disease activity and treatment outcome. We performed a prospective cohort study of 19 treatment-naïve pediatric IBD subjects and 10 healthy controls, measuring fecal calprotectin and assessing the gut microbiome via repeated stool samples. Associations between clinical characteristics and the microbiome were tested using generalized estimating equations. Random forest classification was used to predict ultimate treatment response (presence of mucosal healing at follow-up colonoscopy) or non-response using patients’ pretreatment samples. Patients with Crohn’s disease had increased markers of inflammation and dysbiosis compared to controls. Patients with ulcerative colitis had even higher inflammation and dysbiosis compared to those with Crohn’s disease. For all cases, the gut microbial dysbiosis index associated significantly with clinical and biological measures of disease severity, but did not associate with treatment response. We found differences in specific gut microbiome genera between cases/controls and responders/non-responders including Akkermansia, Coprococcus, Fusobacterium, Veillonella, Faecalibacterium, and Adlercreutzia. Using pretreatment microbiome data in a weighted random forest classifier, we were able to obtain 76.5 % accuracy for prediction of responder status. Patient dysbiosis improved over time but persisted even among those who responded to treatment and achieved mucosal healing. Although dysbiosis index was not significantly different between responders and non-responders, we found specific genus-level differences. We found that pretreatment microbiome signatures are a promising avenue for prediction of remission and response to treatment.
Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept.
Authors: Jennifer Arrondeau, Benoit Blanchet, Audrey Thomas-Schoemann, Olivier Huillard, Pascaline Boudou-Rouquette, Julie Giroux, Anatole Cessot, Camille Tlemsani, Romain Coriat, Jerome Alexandre, Michel Vidal, Francois Goldwasser
Journal: Journal of Clinical Oncology (2015)

2572 Background: Sorafenib is approved in various advanced cancers, including hepatocellular carcinoma (HCC), differentiated iodo-resistant thyroid cancer (DTC), and renal cell carcinoma (RCC). We previously described that sorafenib plasmatic concentrations may decrease over months. We examined the inter-individual variability of sorafenib exposure at the time of disease progression to identify a subset of patients likely to benefit from dose increase. Methods: Patients treated with sorafenib from October 2008 to December 2014 were included in the analysis. Adverse events were prospectively collected and graded using the National Cancer Institute Common Terminology Criteria. The sorafenib plasma concentrations were prospectively determined by liquid chromatography, 30 days after treatment initiation (Cm1) and at disease progression (Cp). Variations of sorafenib concentrations were analyzed using the Wilcoxon test. Results: A total of 124 patients (85 males and 39 females) were studied, 68 having a sorafenib concentration measurement at the time of disease progression. The primary tumor was HCC (n = 46), melanoma (n = 32), DTC (n = 20), RCC (n = 16) or others (n = 9). In the 37 patients without change in dose between treatment initiation and disease progression, the sorafenib dose-normalized concentration decreased significantly over time : median sorafenib Cm1 was 5.54 mg/L while the median sorafenib Cp was 5 mg/L (p = 0.018). When considering all patients at disease progression, 53 patients (43%) had no limiting toxicity, and the inter-individual variation in sorafenib Cp was very large: median Cp 3.82 mg/L; range 2.08-132.9 mg/L. Among the 34 patients with sorafenib Cp < 3.82 mg/L, 22 (65%) had no limiting toxicity, allowing to increase sorafenib dose for treatment optimization, which resulted in clinical benefit in 45% of patients, the more dramatic being 1 complete response in a choroidal melanoma patient, and a 36.9 months disease control in a DTC patient. Conclusions: A subset of patients with disease progression due to sorafenib under-exposure and who may respond after dose increase can be identified using sorafenib plasmatic concentration monitoring.
Prognostic value of blood glucose in Hodgkin's disease.
Authors: A Bisagni, A de Gramont, P Brissaud, M Krulik, D Hubert, A Sirinelli, J Debray
Journal: Journal of Clinical Oncology (1985)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.1.128 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3965630 Prognostic value of blood glucose in Hodgkin's disease. A BisagnixA BisagniSearch for articles by this author , A de GramontxA de GramontSearch for articles by this author , P BrissaudxP BrissaudSearch for articles by this author , M KrulikxM KrulikSearch for articles by this author , D HubertxD HubertSearch for articles by this author , A SirinellixA SirinelliSearch for articles by this author , J DebrayxJ DebraySearch for articles by this author Show More https://doi.org/10.1200/JCO.1985.3.1.128 PDF "Prognostic value of blood glucose in Hodgkin's disease.." Journal of Clinical Oncology, 3(1), pp. 128–129© 1985 by American Society of Clinical Oncology
Metabolic Reprogramming in Brain Tumors
Authors: Sriram Venneti, Craig B. Thompson
Journal: Annual Review of Pathology Mechanisms of Disease (2017)

Next-generation sequencing has substantially enhanced our understanding of the genetics of primary brain tumors by uncovering several novel driver genetic alterations. How many of these genetic modifications contribute to the pathogenesis of brain tumors is not well understood. An exciting paradigm emerging in cancer biology is that oncogenes actively reprogram cellular metabolism to enable tumors to survive and proliferate. We discuss how some of these genetic alterations in brain tumors rewire metabolism. Furthermore, metabolic alterations directly impact epigenetics well beyond classical mechanisms of tumor pathogenesis. Metabolic reprogramming in brain tumors is also influenced by the tumor microenvironment contributing to drug resistance and tumor recurrence. Altered cancer metabolism can be leveraged to noninvasively image brain tumors, which facilitates improved diagnosis and the evaluation of treatment effectiveness. Many of these aspects of altered metabolism provide novel therapeutic opportunities to effectively treat primary brain tumors.
Recombinant Thrombomodulin Safely Controls Disseminated Intravascular Coagulopathy in Acute Promyelocytic Leukemia – Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-P05 Study
Authors: Yuki Yuza, Hiroyuki Takahashi, Hiroshi Moritake, Kiminori Terui, Daiichiro Hasegawa, Kazutoshi Koike, Atsushi Ogawa, Masami Inoue, Daisuke Tomizawa, Takashi Taga, Akio Tawa, Souichi Adachi
Journal: Blood (2014)
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide
Authors: Wolfgang Wick, Patrick Roth, Christian Hartmann, Peter Hau, Makoto Nakamura, Florian Stockhammer, Michael C Sabel, Antje Wick, Susanne Koeppen, Ralf Ketter, Peter Vajkoczy, Ilker Eyupoglu, Rolf Kalff, Torsten Pietsch, Caroline Happold, Norbert Galldiks, Friederike Schmidt-Graf, Michael Bamberg, Guido Reifenberger, Michael Platten, Andreas von Deimling, Christoph Meisner, Benedikt Wiestler, Michael Weller
Journal: Neuro-Oncology (2016)

Optimal treatment and precise classification for anaplastic glioma are needed. The objective for long-term follow-up of NOA-04 is to optimize the treatment sequence for patients with anaplastic gliomas. Patients were randomized 2:1:1 to receive the standard radiotherapy (RT) (arm A), procarbazine, lomustine and vincristine (PCV) (arm B1), or temozolomide (TMZ) (arm B2). Primary endpoint was time-to-treatment-failure (TTF), defined as progression after 2 lines of therapy or any time before if no further therapy was administered. Exploratory analyses examined associations of molecular marker status with TTF, progression-free survival (PFS), and overall survival (OS). At 9.5 (95% CI: 8.6–10.2) years, no difference between arms (A vs B1/B2) was observed: median TTF (4.6 [3.4–5.1] y vs 4.4 [3.3–5.3) y), PFS (2.5 [1.3–3.5] y vs 2.7 [1.9–3.2] y), and OS (8 [5.5–10.3] y vs 6.5 [5.4–8.3] y). Oligodendroglial versus astrocytic histology—but more so the subgroups according to CpG island methylator phenotype (CIMP) and 1p/19q co-deletion status—revealed a strong prognostic value of CIMPpos with (CIMPcodel) versus without 1p/19 co-deletion (CIMPnon-codel) versus CIMPneg. but no differential efficacy of RT versus chemotherapy for any of the endpoints. PFS was better for PCV- than for TMZ-treated patients with CIMPcodel tumors (HR B1 vs B2 0.39 [0.17–0.92], P = .031). In CIMPneg. tumors, hypermethylation of the O6-methyl-guanyl-DNA methyltransferase promoter (MGMT) provided a risk reduction for PFS with chemotherapy. There is no differential activity of primary chemotherapy versus RT in any subgroup of anaplastic glioma. Molecular diagnosis is superior to histology. Trial Registration: clinicaltrials.gov Identifier: NCT00717210.
A randomized, controlled study of nedaplatin or cisplatin concomitant with chemotherapy for advanced non-small cell lung cancer.
Authors: Chunhong Li, Meiyan Liu, Wei Liu, Dandan Li, Li Cai
Journal: Journal of Clinical Oncology (2014)

e19048 Background: Being one of the most malignant tumors commonly seen in clinic, lung cancer has the highest malignant severity and poor chemo-radio-therapeutic efficacy, in which non-small cell lung cancer (NSCLC) accounts for 80%∼85%. As a new anti-tumor drug, nedaplatin (NDP) has similar action mechanisms to cisplatin (DDP), with stronger anti-tumor effects but lower toxicities. This study analyzed and compared the efficacy and safety of NDP or DDP concomitant with chemotherapies in treating advanced NSCLC, hoping to provide references for the reasonable clinical application of NDP in the future. Methods: A retrospective, randomized, control study was conducted, in which 619 NSCLC patients at phases III and IV who were initially treated and re-treated were randomly divided into NDP group (n=294) and DDP group (n=325), and the latter was regarded as control group. Chemotherapeutic protocols (CP/DP/GP/NP/TP) containing NDP/DDP were given to both groups. Short-term efficacy, survival time as well as adverse reactions in both groups were observed after treatment, while patients in both groups were further divided to evaluate the clinical efficacies according to the initial and re-treatment, pathological patterns, types of combined chemotherapeutic protocols, tumor staging and operations. Results: The overall response rate (ORR) and disease control rate (DCR) in NDP group were 48.6% and 95.2%, but 35.1% and 89.2% in DDP group, with statistical significance (p<0.01). In the patients with initial treatment, squamous carcinoma and at phase III, there were significant differences in ORR and DCR (p<0.05), while ORR was significant in patients with adeno-carcinoma, GP/TP and at phase IIIa (p<0.05), and there was significant difference in DCR in patients at phase IIIb (p<0.05). NDP group was significantly longer than DDP group in survival time (p<0.01). The rates of decreased hemoglobin, increased creatinine, nausea and vomiting in NDP group were evidently lower than in DDP group (p<0.05). Conclusions: NDP concomitant with chemotherapy is effective for NSCLC and has higher efficacy, showing certain advantages in prolonging survival time and reducing adverse reactions.
Phage display peptide libraries in molecular allergology: from epitope mapping to mimotope-based immunotherapy
Authors: J. Luzar, B. Štrukelj, M. Lunder
Journal: Allergy (2016)

Identification of allergen epitopes is a key component in proper understanding of the pathogenesis of type I allergies, for understanding cross-reactivity and for the development of mimotope immunotherapeutics. Phage particles have garnered recognition in the field of molecular allergology due to their value not only in competitive immunoscreening of peptide libraries but also as immunogenic carriers of allergen mimotopes. They integrate epitope discovery technology and immunization functions into a single platform. This article provides an overview of allergen mimotopes identified through the phage display technique. We discuss the contribution of phage display peptide libraries in determining dominant B-cell epitopes of allergens, in developing mimotope immunotherapy, in understanding cross-reactivity, and in determining IgE epitope profiles of individual patients to improve diagnostics and individualize immunotherapy. We also discuss the advantages and pitfalls of the methodology used to identify and validate the mimotopes.
Venereal Diseases Today
Authors: Nicholas J. Fiumara, Bernard Appel, William Hill, Herbert Mescon
Journal: New England Journal of Medicine (1959)

THE venereal diseases are so called because they are acquired and spread principally through sexual exposure. They are five in number, and their frequency in the United States is in this descending order: gonorrhea, syphilis, chancroid, lymphogranuloma venereum and granuloma inguinale. The last three have been classed as minor venereal diseases because their incidence and prevalence are considerably less than those of gonorrhea or syphilis. In Massachusetts, as well as in the United States, the minor venereal diseases constitute only 0.5 to 1 per cent of the total cases reported.It is our purpose to summarize the present state of . . .
Defense styles associated with specific anxiety disorders
Authors: C Pollock, G Andrews
Journal: American Journal of Psychiatry (1989)

The Defense Style Questionnaire was administered to control subjects from the general population (N = 204) and to patients with DSM-III panic disorder (N = 39), agoraphobia (N = 39), social phobia (N = 23), or obsessive-compulsive disorder (N = 18). A specific pattern of defenses was associated with each anxiety disorder.
Abstract P146: Circulating Cell-Free DNA Level Associates with Postresuscitation Survival in Out-Of-Hospital Cardiac Arrest Patients
Authors: Chien-Hua Huang, Min-Shan Tsai, Chiung-Yuan Hsu, Wei-Tien Chang, Wen-Jone Chen
Journal: Circulation (2008)

Introduction: Cell-free DNA level, which increases in circulation as a result of tissue injuries, is a novel biomarker for prognosis of clinical diseases. Early biomarker would be helpful for evalu...
Colorectal cancer survivorship statistics: A Veterans Affairs Central Cancer Registry analysis.
Authors: Leah L. Zullig, Valerie Smith, Susanne Danus, Merritt Schnell, Jennifer Lindquist, Dawn T. Provenzale, George L. Jackson, Morris Weinberger, Michael J. Kelley, Hayden B Bosworth
Journal: Journal of Clinical Oncology (2016)

e267 Background: Our objective was to evaluate VA CRC incidence and survival and compare with the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data. Methods: Data were obtained from VACCR for veterans diagnosed/treated in VA for incident CRC during fiscal years (FY) 2009-2012. Using VHA Support Service Center information about the distribution of VA healthcare system enrollees for corresponding years, we adjusted incidence rates for age and gender to the underlying VA population. Survival data were available through January 2015; thus, patients in the analysis had 3-6 years of follow-up data and were censored accordingly. CRC incidence and survival among VA patients was compared to projected national 2014 CRC-specific SEER and supporting data sources. Results: From FY 2009-2012, 12,551 patients (2.6% women; 97.4% men) were in the analytic cohort. Among VACCR patients, the most common tumor location was proximal colon (38%), followed by rectum (31%), distal colon (26%), and other colon (5%). This is comparable to SEER, in which proximal colon and rectum are most common. Among patients in the VACCR, SEER summary stage distribution was: 44% local, 36% regional, 17% distant and 4% unknown. This also aligns with SEER, in which approximately 40% of CRC cases are diagnosed locally. Mirroring SEER, overall VA CRC incidence rate decreased from 0.22 to 0.16 cases per 1,000 veterans in FYs 2009 and 2012. Evaluating survival, median follow-up time was 3.3 years among veterans. The 3-year survival rate for VA patients was 65.9%. Overall 3-year survival is slightly higher for rectal (66.4%) than for colon (65.6%). This is comparable to 5-year SEER survival rates (66.5% and 64.2% for rectal and colon, respectively). Also consistent with SEER, VA CRC patients &lt; 65 have higher rates of 3-year survival than patients &gt; 65 years (74.6% vs. 58.5%, respectively). Conclusions: VACCR data indicate that CRC incidence and survival in FY 2009-2012 approximated SEER projections during a similar timeframe. This suggests that, although VA patients are more complex than the general population, they are diagnosed with comparable CRC locations and stages.
Case 40-1965
Authors: Kenneth T. Bird, Benjamin Castleman
Journal: New England Journal of Medicine (1965)

Presentation of CaseA sixty-four-year-old woman was admitted to the hospital because of unresponsiveness.Seven months previously she had fallen and sustained a bimalleolar fracture of the left ankle, which was placed in a cast for thirteen weeks. She entered a nursing home at that time and had not walked since then because of the fear of falling. She came periodically to the Fracture Clinic, where it was observed that her weight diminished by 5 pounds at each visit. During a brief stay at home one month before admission she was incontinent of stool, anorectic and depressed. Two days before . . .
Objective evaluation of physical activity in Spanish breast cancer survivors.
Authors: Blanca Cantos, Constanza Maximiano, Lidia Brea, Javier Ramos, Juan Antonio Guerra, Diego Malon, Ana Soria, Maria Jesus Ortega, Carmen Fiuza, Marta Montil, Patricia Lopez, Natalia Cascant, Hector Cebolla, Itziar Pagola, Alejandro Lucia, Ana Ruiz-Casado
Journal: Journal of Clinical Oncology (2015)

e20632 Background: Obesity and physical inactivity are poor prognostic indicators for breast cancer. Cardiorespiratory fitness (CRF) is a good predictor of survival for general population and for breast cancer survivors (BCS). CRF depends on genetic factors and on the PA performed by the individual. International organizations recommend at least 150 minutes per week of moderate-vigorous physical activity (MVPA). A limitation of physical activity (PA) research has been the use of self-reported measures. Some studies show that a minority of BCS are meeting the PA recommendations. Methods: BCS with no evidence of disease who had finished their adjuvant treatment were recruited from two different hospitals covering two different areas [Southwest (Group A) and Northwest (Group B) in Madrid-Spain] with a per capita income in the second population X 1,75 times higher than in the first one. They wore an accelerometer during seven days for more than ten hours including two week-end days. Cardiorespiratory fitness was evaluated through the one-mile walk test. Results: 142 women with a history of breast cancer were evaluated. Average moderate and vigorous activity evaluated through an accelerometer was 291,4 minutes/week. Cardiorespiratory fitness 25.8 ml/kg/min. Group A (86 w; 54 yo) had a different educational level than Group B (56w; 53 yo): university education 4% vs 33%; less than high school 63% vs 24%. There were significant differences in IMC (27,9 vs 26,0 kg/m2; p = 0.008); VO2MAX (23.7 vs 28 ml/kg/min; p = 0.006) and MVPA (350.9 vs 231.9 min/week). Conclusions: Though Spanish BCS comply with international recommendations of aerobic physical activity, there could be important differences in the weekly PA, cardiometabolic profile and physical condition depending on socioeconomic environments. Further research including other tumors and other populations is warranted.
Inhibition Of H3K27-Methylome As a Novel Therapeutic Strategy In Multiple Myeloma
Authors: Maria Gkotzamanidou, Masood A Shammas, Jun Qi, Mehmet Kemal Samur, Teru Hideshima, Meletios A. Dimopoulos, Kenneth C. Anderson, James E Bradner, Nikhil Munshi
Journal: Blood (2013)
Why Physicians Hate “Patient Satisfaction”: The Real Reasons
Authors: Ira S. Nash
Journal: Annals of Internal Medicine (2016)

Letters5 July 2016Why Physicians Hate “Patient Satisfaction”: The Real ReasonsIra S. Nash, MDIra S. Nash, MDFrom Northwell Health, Manhasset, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-5009 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:I am pleased that Dr. Kumar agrees that the experience of patients and families is important. That was the central thesis of my article. We also agree that there is no convincing evidence that patient satisfaction is a “proxy” for quality of care. I did not assert that it is. In fact, I believe that patient experience and quality must both be measured precisely because each is important and they are distinct from one another.Dr. Kumar objects to using patient experience scores to modify payments to hospitals and physicians. I did not advocate for using scores this ... Author, Article, and Disclosure InformationAffiliations: From Northwell Health, Manhasset, New York.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-1087. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoWhy Physicians Hate “Patient Satisfaction” but Shouldn't Ira S. Nash Why Physicians Hate “Patient Satisfaction”: The Real Reasons P. Dileep Kumar Metrics Cited byThe Patient Experience and Safety 5 July 2016Volume 165, Issue 1Page: 72KeywordsConflicts of interestDisclosureHealth care qualityMedicarePatient advocacy ePublished: 5 July 2016 Issue Published: 5 July 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The Broad Kinase Inhibitor Dasatinib in Combination with Fludarabine in Patients with Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase 2 Study
Authors: Arnon P. Kater, Marjolijn Spiering, Rob D Liu, Marielle M Beckers, Sanne H. Tonino, Simon M. G. J. Daenen, Jeanette K Doorduijn, Nienke A Lankheet, Dieuwertje M Luijks, Doreen te Raa, Eric Eldering, Marinus H.J. Van Oers
Journal: Blood (2012)